Free Trial

Top Pharmaceutical Stocks To Follow Today - September 21st

Eli Lilly and Company logo with Medical background

Key Points

  • Eli Lilly, AbbVie, and D-Wave Quantum are highlighted as top pharmaceutical stocks to watch, driven by high trading volumes and significant developments.
  • Eli Lilly has potential breakthroughs in diabetes and obesity treatments, reflecting the company's commitment to innovative pharmaceuticals.
  • AbbVie continues to expand its portfolio with treatments for autoimmune diseases and blood cancers, maintaining its focus on diverse therapeutic areas.
  • MarketBeat previews top five stocks to own in November.

Eli Lilly and Company, AbbVie, and D-Wave Quantum are the three Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded companies engaged in the research, development, production and marketing of medicinal drugs. Investors buy these equities to gain exposure to both the high-growth potential of new therapies and the risks tied to clinical trial outcomes, patent expirations and regulatory approvals. Their share prices often react strongly to FDA decisions, pipeline news and changes in healthcare policy. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.

Eli Lilly and Company (LLY)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Read Our Latest Research Report on LLY

AbbVie (ABBV)

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

Read Our Latest Research Report on ABBV

D-Wave Quantum (QBTS)

D-Wave Quantum Inc. develops and delivers quantum computing systems, software, and services worldwide. The company offers Advantage, a fifth-generation quantum computer; Ocean, a suite of open-source python tools; and Leap, a cloud-based service that provides real-time access to a live quantum computer, as well as access to Advantage, hybrid solvers, the Ocean software development kit, live code, demos, learning resources, and a vibrant developer community.

Read Our Latest Research Report on QBTS

See Also

Should You Invest $1,000 in Eli Lilly and Company Right Now?

Before you consider Eli Lilly and Company, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.

While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Looking for Growth? This Tiny AI Stock Has MAJOR Potential
Palantir’s New Deal: Is it an Earnings Signal Investors Can’t Ignore?
From $1 to $15: The Rare Earth Stocks Powering Massive Gains

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines